COMPUGEN overview

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025 PR Newswire HOLON, Israel, Feb. 18, 2025 HOLON, Israel , Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025 , before the U.S. financial markets open. Management will...

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference PR Newswire HOLON, Israel, Feb. 4, 2025 HOLON, Israel , Feb. 4, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference which will take place virtually on February 11, 2025 at...

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors PR Newswire HOLON, Israel, Jan. 8, 2025 New approach to harness cytokine biology to treat cancer patients advances to the clinic First patient dosed with potential first-in-class anti-IL-18 binding protein antibody, COM503, licensed to Gilead Sciences, Inc. Phase 1 dose escalation and dose expansion trial to assess the safety and...

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies PR Newswire HOLON, Israel, Nov. 27, 2024 Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer Further strengthens Compugen's IP portfolio...

Compugen Reports Third Quarter 2024 Results PR Newswire HOLON, Israel, Nov. 12, 2024 Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunotherapy, aligned with previous data presented by the Company Plans to initiate, in Q2 2025, an adaptive platform trial in patients with relapsed platinum sensitive ovarian cancer in the maintenance setting, to evaluate...

Compugen to Participate in Stifel 2024 Healthcare Conference PR Newswire HOLON, Israel, Nov. 11, 2024 HOLON, Israel , Nov. 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen management will participate in a fireside chat at the upcoming Stifel 2024 Healthcare Conference in New York City . The fireside chat will take place on Monday, November 18, 2024 at...

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 PR Newswire HOLON, ISRAEL, Nov. 5, 2024 HOLON, ISRAEL , Nov. 5, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that data supporting the anti-tumor activity and safety profile of the triple combination...

Compugen Strengthens Defence + Security Industry with Strategic Acquisition of SynerSolutions PR Newswire TORONTO, Nov. 4, 2024 TORONTO , Nov. 4, 2024 /PRNewswire/ -- Compugen Inc., the nation's largest privately-owned and operated Technology Ally, is proud to announce the acquisition of SynerSolutions Technologies Inc., a leader in cybersecurity services for defence. Compugen's acquisition of SynerSolutions underscores the company's commitment to delivering industry-leading, human-centric...